No EMA Membership For UK After Brexit, Says European Council
Executive Summary
The European Council’s draft guidelines on the future UK-EU relationship say that the UK, as a third country outside the EU single market, will not be able to participate in any EU agencies after Brexit, dashing hopes expressed by the government that the UK could have “associate membership” of the EMA. However, the UK BioIndustry Association remains optimistic that some form of regulatory cooperation can be negotiated in the interests of all stakeholders.
You may also be interested in...
BIA Wants More Brexit Clarity From UK Regulator As Odds Narrow On ‘No-Deal’ Outcome
The BioIndustry Association is concerned about the lack of clarity on future UK-EU drug regulation after EU heads of state failed to make any tangible progress on Brexit at their much heralded end-of-June summit.
Pharma Backs UK Parliament Report As 'No Deal Brexit' Fears Grow
The pharmaceutical sector has given its backing to a report from MPs which warns that a no-deal Brexit will have a hugely damaging effect on the industry in the country, turning it into "a second-tier state for new and innovative medicines."
UK Health Committee Wants Clear Answers On Future Links Between MHRA And EMA
Sarah Wollaston, chair of the Commons health committee, has asked the government to clarify its intentions for the relationship between the UK MHRA and the EMA during and after any Brexit transition period.